Rapport Therapeutics has seen a sharp pullback recently, and that slump puts fresh focus on whether the current share price ...

Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 ...

Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results ...

Rapport Therapeutics Inc. RAPP stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data. The ...

Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...

Building rapport is a concept that is vital to sales and effective team building. But as a concept, it can be hard to understand because we tend to focus on the wrong parts of what we think are ...

Customers, whether individual consumers or major multinational clients, generally prefer to do business with companies with which they have a good relationship. Companies that have earned good reviews ...

Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...

Shares of Rapport Therapeutics (RAPP) catapulted on Monday after the biotech company's experimental drug significantly reduced seizures in patients with a hard-to-treat form of epilepsy. The company ...

President, Sales Xceleration, leading the organization which focuses on helping small to mid-size businesses get their sales back on track. At its core, selling is about turning leads into prospects ...

NEW YORK--(BUSINESS WIRE)--Rapport, the global out-of-home (OOH) media buying and planning agency arm of IPG Mediabrands, today announced the launch of their newest offering for U.S. clients: ...